Stock Taper 
Agree Realty Corporation is a publicly traded REIT that owns and develops over 1,000 retail properties leased to leading tenants across 45 states, with approximately 21 million square feet of leasable space.
Agree Realty Corporation specializes in acquiring, developing, and managing single-tenant retail properties under net-lease agreements, focusing on expanding its portfolio with recession-resistant, industry-leading tenants nationwide for stable ca...
In early January 2026, Agree Realty Corporation announced its total real estate investment volume for 2025 reached approximately $1.55 billion, encompassing 338 properties. The company also introduced its 2026 investment guidance of $1.25 billion to $1.50 billion, noted as its highest initial guidance in company history. This news highlighted a period of aggressive and successful acquisition activity, reinforcing the company's growth trajectory for investors and analysts.
Both NNN and Agree Realty cut identical deals with tenants, raised guidance the same summer, and dropped nearly the same amount in price last month, yet one of them suits a retiree's portfolio far better than the other.
Monthly dividends sound like a paycheck replacement, but the schedule is the easy part. Three REITs with October checks on the calendar reveal just how different safety, growth, and risk can look behind identical payment frequencies.
Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the successful closing of AstraZeneca's (LSE/STO/NYSE: AZN) strategic equity investment in Summit. The e
Patent discloses uses beyond ADCs, including autologous or allogeneic adoptive cellular immunotherapies like CAR-T, Tregs or TIL cell therapies TAMPA, Fla., Oct. 5, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the United States Patent and Trademark Office has issued U.S. Patent No.
Phase 1/2 APOLLO global clinical trial to evaluate CR-002 in multiple solid tumor types, including non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), on track to initiate in the fourth quarter of 2026
Three income buckets and eight holdings can close the gap between your current savings and a five-figure monthly paycheck, but the math behind each yield level reveals a trade-off most investors never think to calculate.
[url="]Genmab A/S[/url] (Nasdaq: GMAB) today announced results from Part C of the Phase 1/2 RAINFOLâ¢-01 trial evaluating rinatabart sesutecan (Rina-S), an inv
Most retirees lean on Social Security as their primary income, but a dividend portfolio sized correctly could double that monthly check entirely. The catch is that choosing the wrong yield tier could cost you hundreds of thousands of dollars or quietly erode your principal over time.
Simon Property Group and Agree Realty offer 4%+ yields and double-digit total return potential amid sector pullbacks from rising bond yields. SPG's A-rated balance sheet, accelerating NOI, and raised FFO guidance position it well despite $2B in 2024 debt maturities and volatile rates. ADC's investment-grade tenant focus, long-term ground leases, low leverage, and insider buying support its resilience and 4.7% well-covered monthly yield.
Summit Therapeutics Inc. (Nasdaq: SMMT) today announced a clinical trial collaboration agreement with Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE:
Overall rating: B
| PEER | PRICE | |
|---|---|---|
 DLR | $184.50 | COMPARE |
 O | $53.54 | COMPARE |
 REG | $71.03 | COMPARE |
 FRT | $106.20 | COMPARE |
 CUBE | $37.99 | COMPARE |
 BRX | $27.00 | COMPARE |
 FR | $59.78 | COMPARE |
 NNN | $40.13 | COMPARE |
